Hodgkin |
|
New Diagnosis | Relapse / Refractory |
Non-Hodgkin |
|
New Diagnosis | Relapse / Refractory |
Medulloblastoma |
|
New Diagnosis | Relapse / Refractory |
Low-Grade Glioma |
|
New Diagnosis | Relapse / Refractory |
DIPG / High-Grade Glioma |
|
New Diagnosis | Relapse / Refractory |
Ependymoma |
|
New Diagnosis | Relapse / Refractory |
Neurofibromatosis |
|
Sarcoma / MPNST New Diagnosis | Sarcoma / MPNST Relapse / Refractory |
NF2 | Plexiform Neurofibroma |
OPG / Low-Grade Glioma | Other Neurofibromatosis |
Other Brain and Spinal Tumors |
|
ATRT | Craniopharyngioma |
Germ Cell Tumor | Choroid Plexus Tumor |
All Other |
Osteosarcoma |
|
New Diagnosis | Relapse / Refractory |
Ewing Sarcoma |
|
New Diagnosis | Relapse / Refractory |
Rhabdomyosarcoma |
|
New Diagnosis | Relapse / Refractory |
Desmoid Tumors |
|
New Diagnosis | Relapse / Refractory |
Liver |
|
New Diagnosis | Relapse / Refractory |
Kidney |
|
New Diagnosis | Relapse / Refractory |
Retinoblastoma |
|
New Diagnosis | Relapse / Refractory |
Neurofibromatosis |
|
Sarcoma / MPNST New Diagnosis | Sarcoma / MPNST Relapse / Refractory |
NF2 | Plexiform Neurofibroma |
OPG / Low-Grade Glioma | Other Neurofibromatosis |
Melanoma |
|
New Diagnosis | Relapse / Refractory |
Germ Cell Tumor |
|
New Diagnosis | Relapse / Refractory |
All Other Solid Tumors |
|
All Other |
To learn more about available clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
The Cancer and Blood Diseases Institute closely integrates patient care and research to advance knowledge and improve outcomes for our patients. We are known for offering the most advanced therapies − some of which were originally developed here by nationally recognized specialists.
The Oncology Division is a national referral center for specialized leading-edge care of children and young adults with cancer and leukemia and for multidisciplinary long-term follow-up of cancer survivors.
Subscribe to our bi-monthly newsletter for a full list of pediatric, adolescent, and young adult clinical trials.